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Abstract 
Glucagon receptor (GCGR) agonists cause hyperglycemia but also weight loss. However, GCG-like 
peptide 1 receptor (GLP1R)/GCGR mixed agonists do not exhibit the diabetogenic effects often 
attributed to GCGR activity. Thus, we sought to investigate the effect of glucagon agonism on insulin 
action and glucose homeostasis. Acute GCGR agonism induced immediate hyperglycemia, followed by 
improved glucose tolerance and enhanced glucose-stimulated insulin secretion. Moreover, acute GCGR 
agonism improved insulin tolerance in a dose-dependent manner in both lean and obese mice. 
Improved insulin tolerance was independent of GLP1R, FGF21, and hepatic glycogenolysis. Moreover, 
we observed increased glucose infusion rate, disposal, uptake, and suppressed endogenous glucose 
production during euglycemic clamps. Mice treated with insulin and GCGR agonist had enhanced 
phosphorylation of hepatic AKT at Ser473; this effect was reproduced in isolated mouse primary 
hepatocytes and resulted in increased AKT kinase activity. These data reveal that GCGR agonism 
enhances glucose tolerance, in part, by augmenting insulin action, with implications for the use of 
GCGR agonism in therapeutic strategies for diabetes. 
Introduction 
Glucagon (GCG) is a 29–amino acid peptide released from α-cells of the pancreatic islet. Its role as a 
primary counterregulatory hormone to insulin action has long received scientific attention, yet its 
broader therapeutic potential is underappreciated (1,2). Intriguingly, the antidiabetic actions of GCG-
like peptide 1 receptor (GLP1R) agonism are enhanced by the catabolic and hypolipidemic properties of 
GCG receptor (GCGR) agonism (3–5). Importantly, GLP1R/GCGR mixed agonists do not exhibit the 
hyperglycemia and glucose intolerance often attributed to GCGR activity, findings that were confirmed 
in human subjects (6). Moreover, postprandial elevations of GCG and GLP-1 may contribute to 
improved postprandial glucose homeostasis in Roux-en-Y gastric bypass patients (7,8). How GCGR 
monoagonism promotes transient glucose intolerance, yet simultaneously contributes to the 
antidiabetic actions of incretin-based therapies is still unknown. As a counterregulatory hormone with 
a role in maintaining fasting blood glucose, it is tempting to assume that GCG opposes all actions of 
insulin. However, the increased concentrations and action of GCG in the fasting state are well suited to 
potentiate subsequent, insulin-mediated glucose control. In the context of normal physiology, exercise 
induces GCG secretion (9) and modulates the cephalic response of meal assimilation (10). Altogether 
these data suggest that GCG may in fact contribute to these states of heightened insulin sensitivity. 
Chronic GCGR agonism in diet-induced obese (DIO) mice stimulates weight loss, hyperglycemia, and 
glucose intolerance (11). Unexpectedly, GCGR signaling in db/db mice improved the rate of insulin-
stimulated glucose disappearance (kg) (11). Here we demonstrate that, in addition to its 
counterregulatory role, hepatic GCGR agonism enhances systemic insulin-stimulated glucose disposal. 
Together, these data mechanistically elucidate how glucose control may be improved by therapies 
characterized by GCG agonism. 
Research Design and Methods 
Animal Models 
All studies were approved by and performed according to the guidelines of the Institutional Animal 
Care and Use Committee of the University of Alabama at Birmingham or the University of Cincinnati. 
Mice were single or group housed on a 12:12-h light-dark cycle (light on from 0600 h to 1800 h) at 22°C 
and constant humidity with free access to food and water, except as noted. Fgf21-deficient, Gcgr-
floxed, and Glp1r-deficient mice were generated as previously described (12–15), and Alb-Cre mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME). All mice were maintained in our facilities 
on a C57Bl/6J background and fed a standard chow (5.6% fat, Teklad LM-485) or high-fat diet (58.0 
kcal% fat, D12331; Research Diets, New Brunswick, NJ). 
Peptides and Inhibitors 
Novel GCGR agonists (IUB288 and ASP28, GLU29-GCG) were synthesized as previously described 
(11,16). Native GCG and insulin (Humulin R) were obtained from American Peptide Co. and Eli Lilly and 
Co., respectively. Glycogen phosphorylase a/b inhibitor (BAY R3401) was obtained from Sigma-Aldrich 
and diluted in 0.5% methyl cellulose. 
Glucose and Insulin Tolerance Tests 
Glucose and insulin tolerance tests (GTTs and ITTs) were performed in 6 h–fasted 8- to 10-week-old 
chow-fed or 24-week-old DIO male C57Bl/6J mice by i.p. injection of IUB288 (10 nmol/kg) or GCG (10 
nmol/kg) 60 min prior to i.p. injection of glucose (2 g/kg, 20% weight for volume [w/v] d-glucose 
[Sigma-Aldrich] in 0.9% w/v saline) or insulin (0.25–1.0 units/kg in 0.9% w/v saline). ITTs were 
conducted in lean chow-fed male Glp1r−/− and Fgf21∆liver mice at 10–14 weeks old. GTTs and ITTs were 
conducted in 8- to 12- and 10- to 14-week-old Gcgr∆liver mice, respectively. Blood glucose was 
determined by the TheraSense Freestyle Glucometer. Glucose disappearance rate (kg) was defined as 
(Δ blood glucose/min). Insulin and C-peptide were measured from blood collected 60 min after IUB288 
challenge. 
Intravenous Glucose-Stimulated Insulin Secretion and GCGR Agonist Infusion Tests 
Catheters were surgically implanted as previously described (17). Four days after surgery, lean chow-
fed 14-week-old male C57Bl/6J mice were fasted for 5 h. IUB288 injection (10 nmol/kg i.p.) was 
administered 60 min prior to glucose bolus (1 g/kg) delivered via venous catheter. Plasma samples 
were collected immediately before and 2, 5, 10, and 15 min after infusion. For GCGR agonist infusion 
studies, chow-fed 14-week-old male C57Bl/6J mice were fasted for 4 h before 120 min ASP28, GLU29-
GCG infusion (0.00064 and 0.0064 nmol/min). Mice were administered 0.25 units/kg insulin i.p. and 
euthanized 20 min later. 
Euglycemic Clamps 
Clamps were conducted as previously described (17). In brief, catheters were implanted in male 8-
week-old chow-fed C57Bl/6J mice. Four to six days postoperative, mice were fasted for 5 h with saline 
or IUB288 (10 nmol/kg) injected (s.c.) during the final 60 min. Insulin (4 mU/kg/min, diluted in saline) 
was infused through the venous catheter, and euglycemia (140 mg/dL) was maintained by adjusting 
the infusion rate of a 20% glucose solution. A tracer equilibration period (t = −120 to 0 min) was used 
as follows: a 5 µCi bolus of [3-3H]-glucose (PerkinElmer, Boston, MA) was given at t = −120 min 
followed by a 0.05 µCi/min infusion for 2 h. Somatostatin (SST; EMD Millipore, Temecula, CA), mixed 
with the [3-3H]-glucose, was infused at 1.5 µg/kg/min from t = −120 to 0 min and at 3 µg/kg/min 
from t = 0 min to 120 min. At t = 0, [3-3H]-glucose infusion was increased to 0.1 µCi/min to minimize 
changes in specific activity (SA). The variation of SA was <10% from mean during the last 40 min of 
clamp, and the slope of SA over time was not significantly different from t = 0. Blood samples (100 µL) 
were taken at −120, −60, −30, −5, 90, 100, 110, and 120 min for the assessment of glucose, insulin, and 
glucose SA in plasma. Red blood cells from these samples were recovered by centrifugation and 
injected via arterial catheter to prevent a hematocrit deficit. A 10 µCi [1-14C]-2 deoxy-d-glucose ([1-
14C]-2DG) (MP Biomedicals, Santa Ana, CA) bolus was injected at t = 75 min via carotid arterial catheter 
to assess glucose uptake. After the clamp, mice were euthanized and tissues (gastrocnemius, soleus, 
extensor digitorum longus [EDL], quadriceps, liver, gonadal white adipose tissue [WAT], and 
interscapular brown adipose tissue [BAT]) were snap frozen in liquid nitrogen. 
Biochemical Assays 
Plasma [3-3H]-glucose, [1-14C]-2DG, and 3H2O were measured to determine rate of endogenous glucose 
production (Ra), rate of glucose disposal (Rd), and uptake as previously described (17). Clamp plasma 
glucose was measured from 20 µL of deproteinized samples (Glucose Assay Kit; Cell Biolabs, San Diego, 
CA). Tissue-specific [1-14C]-2DG-6-phosphate ([1-14C]-2DGp) content was determined via perchloric 
acid–extracted supernatant with Somogyi procedure (18). Glycogen was assessed from [3-3H]-glucose 
incorporated into ethanol-precipitated glycogen in KOH-digested tissues (19). Plasma glucose SA was 
calculated from the ratio of plasma glucose radioactivity (dpm) over plasma glucose, multiplied by the 
ratio of chemical standard evaporated (CSE) to chemical recovery standard (CRS). The [3-3H]-glucose 
infusion rate (dpm/kg/min) was then calculated from CSE. Rd (mg/kg/min) was determined as the ratio 
of the [3-3H]-glucose infusion rate and the plasma glucose SA of (dpm/mg) at the end of the basal 
period and during the final 30 min of the clamps. Hepatic glucose production rates (Endo Ra; 
mg/kg/min) were determined by subtracting the steady-state glucose infusion rate (GIR) from Rd. 
Plasma [14C]-2DG SA (dpm/mg) was obtained by multiplying the radioactivity disappearance area under 
the curve (AUC) of [14C] in plasma samples by CSE/CRS and then dividing by the average blood glucose 
during the clamped time course. Finally, tissue-specific 2DG uptake (Rg; µg glucose/mg tissue/min) was 
determined as the ratio of the [14C]-2DGp in tissue per tissue weight to plasma [14C]-2DG SA. Plasma 
insulin and C-peptide were measured using mouse ELISA kits (Crystal Chem, Downers Grove, IL). 
Primary Hepatocyte Isolation 
Primary hepatocytes were prepared from anesthetized lean chow-fed male C57Bl/6J mice as previously 
described (20). In brief, perfusion buffer (Krebs Ringer with glucose and 0.1 mmol/L EGTA), followed by 
digestion buffer (Krebs Ringer with glucose, 1.4 mmol/L CaCl2, 50 µg/mL liberase [05401119001; 
Roche]), was infused into the vena cava via peristaltic pump. Hepatocytes were recovered by 
centrifugation (50g 3 min, three times) and seeded on rat tail type 1 collagen–coated plates in DMEM 
(10% FBS, 1% penicillin/streptomycin) with all experiments conducted <24 h postisolation. Hepatocytes 
were serum starved 60 min prior to 2.5 min insulin or GCG treatment for signaling studies. For 
glycogen assay, hepatocytes were fasted overnight in serum-free minimum essential medium alpha (1 
g/L glucose) prior to 2-h insulin or IUB288 treatment with [3-3H]-glucose. 
Immunoblot Analyses 
Cell extracts were prepared in lysis buffer (20 mm Tris [pH 6.8], 3.8 mm dithiothreitol, 10% glycerol, 1% 
SDS, 0.3 mol/L phenylmethylsulfonyl fluoride, and HALT protease inhibitor cocktail [Thermo Fisher 
Scientific]), rotated for 15 min at 4°C, and centrifuged for 10 min at 4°C. Equivalent protein amounts 
were separated by 7.5% SDS-PAGE. Resolved fractions were transferred to polyvinylidene fluoride (Bio-
Rad Laboratories, Hercules, CA), and phosphorylation was detected using phosphospecific antibodies 
to AKT473, AKT308, p44/42 MAPK202/204, forkhead box protein O124 (FOXO124), glycogen synthase kinase 
(GSK) 3α/β21/9 (Cell Signaling Technology, Danvers, MA), and IRS1612 (LifeTechnologies, Frederick, MD). 
Phosphorylation was normalized by TGX stain-free technology and by immunoblot analysis with anti-
AKT, anti-IRS1, FOXO1, and anti-GSK3 (Cell Signaling Technology). Immunoblots were labeled with goat 
anti-rabbit horseradish peroxidase–conjugated secondary antibodies, and protein bands were detected 
and quantified using Clarity ECL, ChemDoc imaging system, and Image Lab 5.0 software (Bio-Rad 
Laboratories). 
AKT Kinase Activity Analysis 
Kinase analysis was performed in freshly isolated primary hepatocytes after 2.5 min of insulin/GCG 
treatments using AKT Kinase Assay Kit (9840; Cell Signaling Technology). Blots from subsequent 
immunoblot analysis were imaged using LumoGLO substrate provided in kit and normalized to total 
protein by TGX stain-free technology. 
Statistics 
All data are represented as mean and SEM. Statistical significance was determined using unpaired 
Student t tests or, where appropriate, one- and two-way ANOVA with multiple comparisons Tukey and 
Sidak posttest, respectively. Statistics were completed using GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software, San Diego, CA) and significance assigned when P < 0.05. 
Results 
Acute GCGR Agonism Enhances Insulin Action and Secretion in Mice 
To interrogate GCGR agonism in glucose metabolism, we administered the GCGR agonist IUB288 
(11,15) to lean chow-fed C57Bl/6J mice via i.p. injection (10 nmol/kg). IUB288 administration resulted 
in a rapid rise in glycemia and a subtle increase in plasma insulin (Fig. 1A and B), both returning to 
baseline levels within 60 min. Surprisingly, an i.p. GTT performed 60 min after single injection of 
IUB288 in lean mice revealed a significant enhancement of glucose tolerance compared with vehicle 
(Fig. 1C). Importantly, this effect was recapitulated by native GCG (Supplementary Fig. 1A and inset). 
Consistent with prior observations of GCGR-enhanced glucose-stimulated insulin secretion (GSIS) (21), 
IUB288 pretreatment (−60 min) increased glucose-stimulated insulin levels in response to an i.v. 
glucose challenge (1 g/kg) (Fig. 1D and inset). These data and previous findings (21) suggest that GCG-
stimulated enhancements in GSIS likely contribute to the improved glucose tolerance after GCGR 
agonism. 
 
Figure 1. GCGR agonism enhances glucose tolerance and insulin secretion. Blood glucose excursion (A) 
and plasma insulin (B) after single i.p. challenge of IUB288 in lean chow-fed C57Bl/6J mice; n = 7–8 
mice/group. Blood glucose (C) during i.p. GTT with acute IUB288 pretreatment in lean mice (n = 27). 
Plasma insulin (D) and AUC (D, inset) during i.v. GSIS with IUB288 pretreatment (n = 7−9). Blood 
glucose excursion (E) and kg 30 (E, inset) during i.p. ITT (0.5 units/kg) with IUB288 pretreatment (s.c. 10 
nmol/kg) at −60 min (n = 17–27). Plasma C-peptide (F) at time 0 and 30 min during 0.5 units/kg i.p. ITT 
(n = 10). See also Supplementary Fig. 1. All data are represented as mean ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001, vs. vehicle control mice. 
 
Acute GCGR Agonism Enhances Insulin Sensitivity in Mice 
Although GCGR-dependent potentiation of GSIS may contribute to enhanced glucose tolerance, this 
mechanism is unlikely to account for any enhancement of insulin action. To assess the effects of GCGR 
agonism on insulin-dependent glucose disposal, we treated lean mice with IUB288 60 min prior to an 
ITT (0.5 units/kg). IUB288 significantly enhanced the response to insulin, as determined by both the 
nadir glucose and the calculated kg over the initial 30-min period (Fig. 1E). To assay endogenous insulin 
during this test, we measured circulating C-peptide (Fig. 1F) and observed that the enhanced insulin 
action was independent of increased insulin secretion. Importantly, this sensitizing effect was 
recapitulated by native GCG during both 0.25 units/kg and 0.5 units/kg ITTs without an increase in 
circulating C-peptide (Supplementary Fig. 1B–D) and was similarly observed during coadministration of 
IUB288 and insulin (Supplementary Fig. 1E). 
To assess how long improved insulin action remained evident after GCGR agonism, we increased the 
pretreatment period (i.e., from 60 to 180 min). Even after this extended pretreatment, we observed a 
beneficial and dose-dependent effect of IUB288 on insulin action during the ITT (Supplementary Fig. 
1F and G). We next assessed insulin sensitivity after GCGR agonism using ITTs across a range of insulin 
doses (0.25–1 units/kg). These studies revealed a clear enhancement in insulin action at multiple 
insulin doses (Fig. 2A–D), resulting in increased kg 30 in both lean (Fig. 2E) and DIO mice compared 
with the vehicle controls (Fig. 2F and Supplementary Fig. 2A–D). Similarly, continuous infusion of the 
short-acting GCGR agonist ASP28, GLU29-GCG 120 min prior to administration of a subthreshold i.p. 
insulin bolus (0.25 units/kg) increased kg 20 after GCGR stimulation (Fig. 2G and inset). Importantly, 
this insulin-sensitizing effect occurred in the absence of prior hyperglycemia (Fig. 2G), demonstrating 
independence from GCG-induced hyperglycemia. 
 
Figure 2. GCGR agonism enhances insulin action across a range of insulin doses. Blood glucose 
excursion during i.p. ITT at 0.25 (A), 0.50 (B), 0.75 (C), and 1.0 units/kg insulin (D) in lean chow-fed mice 
with simultaneous cotreatment with IUB288 (10 nmol/kg). Rate of glucose change (kg 30) (E) calculated 
from data in panels A–D. Rate of glucose change (kg 30) (F) of DIO mice (data from Supplementary Fig. 
2). Blood glucose excursion (G) and kg 20 (G, inset) after 120 min of continuous ASP28, GLU29-GCG 
treatment via jugular infusion (n = 7–9). See also Supplementary Figs. 1 and 2. All data are represented 
as mean ± SEM. n = 8 mice/group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
 
Glucagon can activate both stimulatory and inhibitory G-protein pathways via GLP1R (22). To 
investigate potential GLP1R cross-activation, we conducted an i.p. ITT with IUB288 pretreatment in 
GLP1R-deficient (Glp1r−/−) mice. We found similar insulin-dependent glucose lowering after IUB288 
injection in Glp1r−/− mice when compared with their wild-type (WT) littermates (Supplementary Fig. 
3A and B). Likewise, we have reported that GCGR agonism induces the expression and secretion of 
FGF21, a known insulin sensitizer (11). However, IUB288 improved insulin sensitivity in global (data not 
shown) and liver-specific, FGF21-deficient (Fgf21∆liver) mice to a similar extent as observed in control 
mice (Supplementary Fig. 3C and D). Together these data suggest that acute GCGR agonism enhanced 
insulin sensitivity independent of GLP1R signaling or FGF21. 
To gain insights into factors contributing to this enhancement of the insulin-dependent glucose 
metabolism, we performed euglycemic clamps. We conducted these clamps (Fig. 3A–E) with 
continuous SST infusion (1.5 µg/kg/min during the preinsulin basal condition and 3 µg/kg/min during 
insulin infusion, which was maintained through the termination of the clamp) to control for increased 
insulin levels observed in IUB288-treated mice (Fig. 1). We also included d-[3-3H]-glucose to interrogate 
hepatic glucose metabolism and [14C]-2DG to assess tissue-specific glucose uptake. Mice receiving 
IUB288 initially displayed hyperglycemia (Fig. 3A) that was resolved by the second hour of insulin 
infusion. However, under clamp conditions (t = 90–120), we observed a striking increase in GIR in 
IUB288-treated mice (Fig. 3B). Importantly, we observed similar GIR potentiation in euglycemic clamp 
studies conducted without SST (data not shown). Plasma insulin measured at baseline (t = 0) and 120 
min in our SST-based euglycemic clamp revealed a slight elevation (P = 0.0025, two-way ANOVA) (Fig. 
3C). Importantly, the enhanced GIR observed in IUB288-treated mice was not attributable to 
differential levels of circulating insulin (Fig. 3C). Rd was likewise increased over vehicle treatment (Fig. 
3D). Altogether, these data demonstrate that GCGR agonism enhances whole-body insulin sensitivity. 
 
Figure 3. GCGR agonism enhances hepatic insulin sensitivity during euglycemic clamp. Blood glucose (A) and GIR 
(B) during labeled euglycemic clamp. Plasma insulin (C), Rd (D), Ra (E), and suppression of Ra (E, inset) during 
labeled euglycemic clamp. All data are represented as mean ± SEM (n = 6–7 mice). See also Supplementary Fig. 
5. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, vs. baseline time point; #P < 0.05, ##P < 0.01, and 
###P < 0.001, vs. vehicle within time points. 
 
Ra in IUB288-treated mice was reduced to a greater extent as compared with vehicle controls (P < 
0.0001 in steady state) (Fig. 3E and inset), suggesting hepatic insulin sensitivity was enhanced despite 
the fact that baseline Ra was predictably elevated by IUB288 (P < 0.01). GCGR agonism significantly 
reduced liver glycogen content during euglycemic clamp (P < 0.01) (Fig. 4A). Likewise, insulin failed to 
revert the reduction in glycogen promoted by IUB288 in isolated primary hepatocytes (Fig. 4B). 
Hepatocyte glycogen depletion enhances glycogen synthesis and glucose uptake (23) and also 
stimulates adipocyte lipolysis via a hepatic–central nervous system–adipose signaling axis (24). To test 
if depletion of hepatic glycogen stores also acts as a precipitating signal to enhance whole-body insulin 
sensitivity, we blocked glycogenolysis via the glycogen phosphorylase a/b inhibitor BAY R3401 (25). 
BAY R3401 was administered 60 min prior to IUB288 treatment (i.e., t = −120) and was sufficient to 
block 70% of the acute GCGR agonist–stimulated hyperglycemia and to reduce glycemia in lean chow-
fed mice (Supplementary Fig. 4A and B). BAY R3401 pretreatment likewise improved glucose tolerance 
(Supplementary Fig. 4C), yet did not reduce the incremental AUC, in these mice (Supplementary Fig. 
4D, bars 1 and 3). As in our prior studies, IUB288 pretreatment induced transient hyperglycemia, yet 
improved glucose tolerance (excursion and incremental AUC), in vehicle-pretreated mice 
(Supplementary Fig. 4C and D). However, inhibition of glycogenolysis failed to reduce GCG-stimulated 
enhancement of glucose tolerance (Supplementary Fig. 4D, bars 2 and 4). Altogether, these data 
suggest that GCGR signaling cooperates with insulin to reduce glucose output independent of its 
effects on glycogen metabolism. 
 
Figure 4 GCGR agonism enhances insulin-stimulated nonhepatic glucose uptake during euglycemic clamp. Liver 
and quadriceps glycogen content (A) after labeled euglycemic clamp. Cellular glycogen levels (B) after 2-h 
IUB288 or IUB288 and insulin cotreatment in primary hepatocytes (n = 3–4 observations). [14C]-2DG uptake into 
EDL, quadriceps, gastrocnemius, soleus, and epididymal WAT (C) and BAT (D). All data are represented as mean 
± SEM (n = 6–7 mice). See also Supplementary Fig. 5. *P < 0.05; ***P < 0.001; ****P < 0.0001. 
 
Unlike in liver, skeletal muscle glycogen was unchanged by IUB288 (Fig. 4A). However, we observed 
elevated [14C]-2DG uptake into EDL, quadriceps, gastrocnemius, and soleus (Fig. 4C). In contrast to 
skeletal muscle, glucose uptake was unchanged in WAT (Fig. 4C), yet BAT appears to be the primary 
site of IUB288-stimulated glucose disposal, as [14C]-2DG accumulation was increased by fivefold 
compared with saline (P < 0.005) (Fig. 4D). 
Interaction of Hepatic Glucagon and Insulin Receptor Signaling 
Considering high-level expression of both GCGR and insulin receptor (INSR) in liver, we reasoned that 
hepatic interaction between GCGR and INSR signaling pathways contributed to enhanced insulin 
sensitivity. We injected chow-fed mice with IUB288 or vehicle 60 min prior to an i.p. bolus of insulin or 
vehicle. Ten minutes later, components of the insulin signaling pathway were analyzed in liver tissue. 
IUB288 pretreatment increased the insulin-stimulated phosphorylation at AKTSer473, but not 
AKTThr308 (Fig. 5A–C), suggesting that GCGR-stimulated enhancement of insulin sensitivity may rely 
upon a site-specific potentiation of AKT phosphorylation. We next treated isolated hepatocytes with 
GCG over a range of insulin concentrations to assess cell-autonomous interactions between GCGR and 
INSR signaling. Phosphorylation of IRS1Tyr612 and AKTThr308 by insulin was unaffected by the GCG 
cotreatment (Fig. 5D and F and Supplementary Fig. 5A and B). Consistent with our in vivo studies, GCG 
cotreatment directly enhanced insulin-stimulated AKTSer473 phosphorylation (Fig. 5E). We also observed 
enhanced phosphorylation of the AKT target, GSK3α/β (P < 0.01) (Supplementary Fig. 5A–D), but not 
FOXO1 (Supplementary Fig. 5A and B). 
 
Figure 5. Convergence of GCGR and insulin signaling at AKT. Immunoblot analysis of liver AKT phosphorylation in 
response to insulin and IUB288. IUB288 (10 nmol/kg) injected 60 min prior to 10-min insulin challenge. 
Representative images of phosphorylation on residues Ser473 and Thr308 (A) and densitometric quantification 
(B and C) of seven to eight mice per group. Immunoblot analysis of hepatocyte insulin signaling in response to 
insulin and GCG cotreatment (D–F). Representative images (D) and densitometric quantification (E and F) of six 
independent observations. Kinase activity analysis of hepatocyte AKT in response to insulin and IUB288 
cotreatment. Representative image of in vitro phosphorylation of exogenous AKT substrate (GSK3) (G). 
Densitometric quantification (H) of four independent observations. See also Supplementary Fig. 6. All data are 
represented as mean ± SEM. *P < 0.05, vs. baseline time point; #P < 0.05 and ##P < 0.01, vs. vehicle within time 
points. 
 
To directly test for enhanced AKT activity, we measured kinase activity of isolated AKT in vitro. 
Phosphorylated AKT was immunoprecipitated from primary hepatocyte cell lysates prior to incubation 
with a target peptide. Similar to our observations in liver tissue and isolated hepatocytes, insulin-
stimulated AKT activity was significantly enhanced by cotreatment with GCG (Fig. 5G and H). Together 
these data suggest that GCGR-dependent enhancement of insulin sensitivity is mediated via increased 
AKT activity. 
Analysis of liver samples from clamped mice identified a similar increase in liver 
AKTSer473 phosphorylation (Supplementary Fig. 6A and E) with reduced phosphorylation at IRS1Tyr612, 
AKTThr308, and p44/42 MAPKThr202/Tyr204 (Supplementary Fig. 6B–E). Although glucose uptake was 
enhanced in EDL, AKTSer473 phosphorylation was reduced in this tissue, whereas 
AKTThr308 phosphorylation was elevated and phosphorylation at IRS1Tyr612 and p44/42 
MAPKThr202/Tyr204 was unchanged (Supplementary Fig. 6A–D and F). Finally, in BAT, where glucose 
uptake was most positively regulated, phosphorylation at AKTSer473, AKTThr308, and p44/42 
MAPKThr202/Tyr204 were all enhanced, with a similar trend at IRS1Tyr612 (Supplementary Fig. 6A–D and G). 
Together these data further support a direct and indirect contribution of multiple tissues to the GCGR-
dependent enhancement of glucose clearance. 
Hepatic Glucagon Receptors Contribute to GCGR-Mediated Improvements in Insulin 
Action 
To investigate the physiological contribution of hepatic GCGRs, we used mice deficient for 
hepatic Gcgr (Gcgr∆liver). As previously described (14,15), these mice exhibit reduced fasting blood 
glucose (Fig. 6A), are refractory to a single provocative IUB288 challenge (Fig. 6B), and display 
dramatically enhanced glucose tolerance (Fig. 6C). Unlike in WT mice, IUB288 had little effect on 
glucose excursion in Gcgr∆liver mice (Fig. 6C and D). To further dissect the contribution of the hepatic 
GCGR, we challenged mice with an ITT (0.25 units/kg) and observed reduced blood glucose (Fig. 6E) 
and enhanced kg (Fig. 6F) in WT, but not Gcgr∆liver, mice. Moreover, GCG cotreatment enhanced insulin-
stimulated AKTSer473 phosphorylation in isolated primary hepatocytes from WT, but not Gcgr∆liver, mice 
(Fig. 6G and H), suggesting that hepatic GCGR signaling contributes to insulin-dependent improvement 
in glycemic control. 
 
Figure 6. Hepatic receptors contribute to GCGR-mediated improvements in insulin action. Fasting blood glucose 
(A) and i.p. IUB288-stimulated blood glucose excursion (B) in WT and Gcgr∆liver mice. GTT (C) and AUC analysis (D) 
in WT and Gcgr∆liver mice with IUB288 pretreatment. ITT (E) and kg 15 analysis (F) in WT and Gcgr∆liver mice with 
60-min IUB288 pretreatment administered s.c. at 10 nmol/kg throughout. Immunoblot analysis of AKT 
phosphorylation in response to insulin and GCG cotreatment in hepatocytes isolated from WT or Gcgr∆liver mice 
(G and H). All data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, WT 
vehicle vs. WT IUB288; #P < 0.05, Gcgr∆liver vehicle vs. Gcgr∆liver IUB288; &&P < 0.01, WT insulin vs. WT insulin + 
IUB288; $$$$P < 0.0001, WT insulin + IUB288 vs. Gcgr∆liver insulin + IUB288. 
 
Discussion 
Data presented here elucidate a novel role for GCGR signaling in insulin sensitivity. As a 
counterregulatory hormone, it is tempting to assume that GCG opposes all of insulin’s actions. 
However, GCG secretion and action in the fasting state make it well-suited to potentiate subsequent 
insulin action. In normal physiology, these data and the previously described prandial GCG spike (26) 
suggest that GCG may act as a preparatory component for the postprandial state. Thus, whereas 
chronic GCGR activation impairs glucose tolerance, acute agonism synergistically enhances insulin 
action and may also potentiate glucose-dependent insulin secretion. 
Mechanistically, we observed that hepatic GCGR-deficient mice were resistant to GCG-mediated 
potentiation of insulin action, suggesting that the liver is likely the primary site of action. Although 
these findings highlight the liver (and presumably hepatocytes) as the tissue responsible for this novel 
GCGR action, a caveat must be acknowledged in this interpretation. Specifically, the Gcgr∆liver mouse is 
characterized by supraphysiological levels of GLP-1 and FGF21 (27), both potent sensitizers of insulin 
action, which may contribute to the reported improvement in glucose tolerance (27). In the context of 
this study, these factors may act to mask any subtle differences between the IUB288- and vehicle-
pretreated Gcgr∆liver mice. Consistent with this observation, we observed a small, but statistically 
significant, difference in glucose excursion between the IUB288- and vehicle-pretreated Gcgr∆liver mice 
30 min after glucose challenge. Thus, although the liver is likely the primary site of action, it is possible 
that the direct potentiation of AKTSer473 phosphorylation and subsequent activity observed in liver may 
also occur in other tissues. 
The acute action of GCGR agonsim to elevate glycemia invokes the possibility that this transient 
hyperglycemia may trigger insulin secretion and thus improve glucose homeostasis. However, infusion 
of a short-acting GCGR agonist at doses insufficient to induce hyperglycemia still resulted in a clear and 
significant increase in insulin action. Likewise, blockade of glycogenolysis (via BAY R3401) 
(Supplementary Fig. 4) ablated GCGR agonist–induced hyperglycemia, but not IUB288 enhancement of 
glucose tolerance. Moreover, our euglycemic clamp protocol included continuous SST infusion to 
eliminate potential endogenous insulin secretion. We observed GCG-enhanced insulin actions, 
including improved glucose tolerance, suppressed hepatic glucose output, and enhanced glucose 
uptake in the presence of SST. Together we interpret these data to suggest that insulin secretion, 
downstream of GCGR agonist–induced hyperglycemia, is not the mechanism underlying this enhanced 
glucose homeostasis. 
Although these data cannot exclude a possible cross-activation of other receptors (i.e., GIPR), these 
insulin-sensitizing effects are clearly GCGR dependent. Along these lines, hepatic glycogen is known to 
regulate adipocyte lipolysis via a hepatic–central nervous system–adipose signaling axis (24). This 
regulatory pathway is of interest in that it is stimulated by depleted hepatic glycogen levels, similar to 
what we observe after GCGR agonsim. However, pharmacological blockade of glycogenolysis had no 
effect on GCG-stimulated enhancement of glucose tolerance. We interpret these results to conclude 
that the effects of GCGR agonsim on glucose tolerance are independent of its effects on glycogen 
metabolism. Although we hypothesize that GCGR and INSR signaling are interacting in a cell-
autonomous manner at the hepatocyte, insulin also suppresses hepatic glucose production via 
reduction of circulating free fatty acids (28) (i.e., independent of liver INSR or GCGR signaling). Thus, 
although the liver is likely the primary site of action, it is possible that the direct potentiation of 
AKTSer473 phosphorylation and subsequent activity observed in liver may also occur in other tissues. Of 
particular note was the enhanced uptake observed in skeletal muscle. Given that GCGR is poorly 
expressed in skeletal muscle (if at all) (29), this effect is likely mediated indirectly via an alternative 
endocrine signal and not the direct interactions of GCGR and INSR signaling in these cells. 
Importantly, during the preparation of this article, Alonge et al. (30) reported the cooperative 
intersection of GCG and insulin signaling in the transcriptional regulation of Fgf21 expression. This 
report, along with our current studies, provides strong evidence for intracellular and cooperative 
overlap between these two counterregulating hormones. The physiological relevance of 
Ser473 phosphorylation is controversial. However, an emerging view suggests that it precedes 
Thr308 phosphorylation, facilitating activation by PDK1 (31). The mechanistic target of rapamycin 
complex 2 (mTORC2) is responsible for insulin-stimulated AKTSer473 phosphorylation (32). Thus, 
potentiation of Ser473 phosphorylation suggests that GCGR agonism may augment this pathway. 
However, other known mTORC2 targets, paxillin, protein kinase Cα (33), and the serum- and 
glucocorticoid-induced protein kinase (34), remained unaffected by GCG (data not shown). These data 
suggest target-specific activation of the complex after GCGR agonism, or inhibition of a phosphatase 
specifically targeting AKT-Ser473, such as PH domain leucine-rich repeat protein phosphatase (35). 
Testing these hypotheses will require further experimentation. 
The findings described here add to the growing therapeutic attributes of GCGR activation. Specifically, 
recent reports suggest that coagonists containing GCGR activity produce superior glucose control as 
compared with GLP-1, GIP, or thyroid hormones alone (3–5,36). Likewise, our data may provide 
mechanistic insight into the paradoxical improvements in the average level of glycemia and a reduction 
in hyperglycemic events observed in patients using a wearable, bihormonal (GCG and insulin) bionic 
pancreas (37). Thus, these data suggest that GCGR agonism acts both at the level of the liver and 
pancreas to improve postprandial glycemia. Further, they provide mechanistic insight into the 
“paradoxical” improvement in glucose homeostasis seen in GCGR-targeted therapeutics. 
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